1. Show article details.

    After Merck success, work goes on with other Ebola vaccines

    Reuters – 11:29 AM ET 07/31/2015

    Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics (NLNK) proving 100 percent effective in a trial in Guinea. Experts said on Friday different kinds of vaccines were needed that might be better suited for different population groups.

  2. Show article details.

    Merck Earnings Hurt by Arthritis Drug Knockoffs

    DJ Business News – 8:05 AM ET 07/28/2015

    Low-cost knockoffs of the arthritis treatment Remicade in Europe hurt Merck& Co.' s second-quarter sales and earnings, a harbinger of the pressure facing sellers of other costly biotechnology drugs in the coming years. Merck, which handles Remicade marketing in Europe, said the company's sales of the drug declined 25% to $455 million for the quarter, as European doctors prescribed copycat versions that cost up to 45% less than the branded drug. Companies including Hospira Inc....

  3. Show article details.

    Horizon Boosts Depomed Bid to About $2 Billion

    DJ Business News – 1:05 PM ET 07/21/2015

    Horizon Pharma PLC (HZNP) ramped up its pursuit of Depomed Inc. (DEPO), increasing its bid for the company to about $2 billion in a proposed all-stock deal. Still, shares of Depomed (DEPO) traded above the revised offer price Tuesday, indicating investors may not think the bid will be enough to secure a deal. Shares of Depomed (DEPO) were up 2.3% to $33.50 midday, while Horizon shares fell 0.3% to $37.20.

  4. Chevron leads Dow gainers, up 0.6% in early trade

    MarketWatch – 9:36 AM ET 07/21/2015
  5. Show article details.

    Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2015

    PR Newswire – 11:40 AM ET 07/20/2015

    NEW BRUNSWICK, N.J., July 20, 2015 Johnson & Johnson today announced that its Board of Directors has declared a cash dividend for the third quarter of 2015 of $0.75 per share on the company's common stock. About Johnson & JohnsonCaring for the world, one person at a time, inspires and unites the people of Johnson & Johnson.

  6. Show article details.

    Two new trials of Ebola vaccines begin in Europe and Africa

    Reuters – 7:33 AM ET 07/15/2015

    Two new Ebola vaccine trials began on Wednesday with volunteers in Britain, France and Senegal getting "prime-boost" immunisations developed by Bavarian Nordic (BVNKF), GlaxoSmithKline and Johnson & Johnson (JNJ). The mid-stage, or Phase II, trials are designed primarily to test the vaccines' safety, but will also assess whether they provoke an immune response against the deadly virus.

  7. Show article details.

    Greece bans export of 25 drugs after pharmacists' supply warnings

    Reuters – 11:59 AM ET 07/14/2015

    Greece has decided to ban the export of 25 types of drugs, the Health Ministry said on Tuesday, following warnings of possible shortages that risked leading to a humanitarian crisis. A ministry spokeswoman quoted the Greek drugs regulator as saying there had been a significant increase in some imported medicines being shipped back out of the country.

  8. Show article details.

    BRIEF-J&J CFO sees little impact from Greece debt resolution

    Reuters – 11:07 AM ET 07/14/2015

    Johnson & Johnson (JNJ). * J&J CFO says does not expect Greece debt resolution to affect company sales, earnings unless there is significant change from expected resolution. * CEO says patent protects Remicade until 2018 from biosimilars Further company coverage:

  9. Johnson & Johnson down 1.4% to top Dow laggards

    MarketWatch – 9:39 AM ET 07/14/2015
  10. Show article details.

    U.S. Stocks Extend Gains

    DJ Business News – 8:45 AM ET 07/14/2015

    U.S. stocks rose Tuesday, pushing the Dow industrials index back above 18,000 for the first time in three weeks. The day extended the rally in stocks to four sessions. With Tuesday's gains, the S&P 500 is up 2.4% and the Dow is up 1.3% for the year.

  11. Show article details.

    J&J's Nonprescription Business Could Soon Get a Lift

    DJ Business News – 8:25 AM ET 07/14/2015

    A Philadelphia-area Johnson& Johnson factory at the center of dozens of product recalls in recent years is getting close to reopening after a long overhaul, the company said Tuesday, a big step in J&J's efforts to revive its non- prescription-medicines business. The Fort Washington, Pa., plant was closed in 2010 after J&J recalled more than 135 million medicine bottles when customers found, for instance, tiny metal particles floating in children's Tylenol. Since then, J&J has been...

  12. Show article details.

    J&J Lifts Earnings Outlook Despite Impact From Stronger Dollar

    DJ Business News – 8:14 AM ET 07/14/2015

    Johnson& Johnson on Tuesday boosted its earnings guidance for the year as results topped expectations in its second quarter. J&J said it now expects to post per-share earnings of $6.10 a share to $6.20 a share, up from its previous guidance of $6.04 a share to $6.19 a share. Shares, relatively flat over the past three months, edged up 0.7% in premarket trading.

  13. Show article details.

    Johnson & Johnson second-quarter sales wilt on strong dollar, weak device sales

    Reuters – 8:05 AM ET 07/14/2015

    - Johnson & Johnson (JNJ) on Tuesday reported sharply lower sales in the second quarter, and cited a stronger U.S. dollar, disappointing sales of its medical devices and plunging demand for a hepatitis C drug faced with strong competition.

  14. Show article details.

    J&J's stock gains after Q2 profit beat expectations

    MarketWatch – 7:58 AM ET 07/14/2015

    Johnson& Johnson's stock tacked on 0.7% in premarket trade Tuesday, after the drug and consumer products company reported a second-quarter profit that beat expectations and adjusted its outlook higher. Net earnings rose to$ 4.52 billion, or $1.61 a share, from $4.33 billion, or $1.51 a share, in the same period a year ago. Excluding non- recurring items, adjusted earnings per share came in at $1.71, above the FactSet consensus of $1.68.

  15. J&J's stock gains 0.7% premarket after Q2 results

    MarketWatch – 7:49 AM ET 07/14/2015
  16. J&J lifts 2015 adj. EPS outlook to $6.10-$6.20 from $6.04-$6.19

    MarketWatch – 7:48 AM ET 07/14/2015
  17. J&J Q2 sales $17.79 bln vs. $19.5 bln; FactSet consensus $17.76 bln

    MarketWatch – 7:47 AM ET 07/14/2015
  18. J&J Q2 adj. EPS $1.71 vs. FactSet consensus $1.68

    MarketWatch – 7:47 AM ET 07/14/2015
  19. Johnson & Johnson Q2 EPS $1.61 vs. $1.51 a year ago

    MarketWatch – 7:46 AM ET 07/14/2015
  20. Show article details.

    Johnson & Johnson Reports 2015 Second-Quarter Results:

    PR Newswire – 7:45 AM ET 07/14/2015

    NEW BRUNSWICK, N.J., July 14, 2015 Johnson & Johnson (JNJ) today announced sales of $17.8 billion for the second quarter of 2015, a decrease of 8.8% as compared to the second quarter of 2014. Net earnings and diluted earnings per share for the second quarter of 2015 were $4.5 billion and $1.61, respectively.


Today's and Upcoming Events

  • Aug

    JNJ ex-Dividend for $0.75 on 8/21/2015

    • Announce Date: 7/20/2015
    • Record Date: 8/25/2015
    • Pay Date: 9/8/2015
  • Oct

    JNJ to announce Q3 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.